Search results
Tumors shrink for 62% of patients in Merck study
Becker’s Hospital Review· 7 days agoIn a phase 2/3 trial investigating the efficacy of Keytruda with two chemotherapies, tumors shrank among 3 in 5 patients with pleural mesothelioma, Merck said May 29. It often progresses rapidly ...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 15 hours agoThis study assessed Tagrisso in combination with pemetrexed and platinum-based chemotherapy in 557...
BMS secures another EC approval for Opdivo combination
Pharmaceutical Technology via Yahoo Finance· 6 days agoPreviously, there were no marketed therapies that improved overall survival in patients with...
Secondhand Smoke Increases Cisplatin Resistance in HNC
Medscape· 6 days agoDr Maurie Markman discusses results from a study suggesting that secondhand smoke exposure may...
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
Zacks via Yahoo Finance· 7 hours agoBristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy...
ASCO 2024: AbbVie flexes early success of ADC pipeline in solid tumours
Clinical Trials Arena via Yahoo Finance· 2 days agoThe therapy was evaluated as a monotherapy and in combination with AbbVie’s investigative programmed...
EMA Panel Nods to Seven New Cancer Drugs
Medscape· 5 days agoThe drugs include an anti–PD-L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers.
Engineered DNA 'warhead' targets a common cancer mutation
Medical Xpress· 5 days agoTumor protein P53 (TP53) plays an important role in suppressing the growth of tumors. Mutations in the gene for TP53 can have a disastrous effect, hampering the body's ability to fight tumors ...